NQTrp

Research use only, not for human use.

NQTrp is an inhibitor of the aggregation of the tau protein with generic anti-amyloidogenic effects.

NQTrp is an inhibitor of the aggregation of the tau protein with generic anti-amyloidogenic effects.(In Vitro):NQTrp inhibits the in vitro aggregation of hexapeptide (41GCWMLY46 within the N-terminus of γD-crystallin) as well as full-length γD-crystallin. NQTrp effectively inhibits the fibrillation of the GDC6 peptide (50 μM) in a dose-dependent manner and prevents the formation of elongated amyloid fibrils. NQTrp has no toxic effect toward retinal cell culture and reduces the cytotoxicity induced by aggregates of the hexapeptide(IC50=70 μM) in ARPE-19 cells. In TEM analysis, GDC6 peptide fibrils (50 μM) in the presence of NQTrp 5:1, 1:1, 1:5 ratio (GDC6: NQTrp).

In TEM analysis, GDC6 peptide fibrils (50 μM) in the presence of NQTrp 5:1, 1:1, 1:5 ratio (GDC6: NQTrp). NQTrp effectively inhibits the fibrillation of the GDC6 peptide (50 μM) in a dose-dependent manner and prevents the formation of elongated amyloid fibrils.NQTrphas no toxic effect toward retinal cell culture and reduces the cytotoxicity induced by aggregates of the hexapeptide(IC50=70 μM) in ARPE-19 cells.

——

——

Cytoskeleton/Cell Adhesion Molecules

Microtubule/Tubulin

Platelet aggregation

——

——

185351-19-3

360.36

C21H16N2O4

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (346.88 mM)

OC([C@H](Cc1c[nH]c2c1cccc2)NC(C(c1c2cccc1)=O)=CC2=O)=O

——

(-20℃)

With Ice Pack

≥ 2 years